{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T10:40:17Z","timestamp":1762425617372,"version":"build-2065373602"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-025-11185-9","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T10:35:19Z","timestamp":1762425319000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting SRPK1 to regulate alternative splicing in prostate cancer: the roles of MALAT1 and TUG1"],"prefix":"10.1007","volume":"53","author":[{"given":"Linomtha","family":"Gabada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Afra","family":"Basera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Babatunde Adebola","family":"Alabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zodwa","family":"Dlamini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahaba","family":"Marima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"issue":"3","key":"11185_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"11185_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.euros.2022.11.002","volume":"53","author":"M Arnold","year":"2024","unstructured":"Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M et al (2024) Global burden of prostate cancer: Incidence, mortality and disability-adjusted life years from GLOBOCAN 2020. Eur Urol Open Sci 53:1\u201312. https:\/\/doi.org\/10.1016\/j.euros.2022.11.002","journal-title":"Eur Urol Open Sci"},{"issue":"1","key":"11185_CR3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00345-023-04509-6","volume":"42","author":"M Mistry","year":"2024","unstructured":"Mistry M, Parkin DM, Ferlay J (2024) Global patterns and trends in prostate cancer incidence and mortality. World J Urol 42(1):45\u201354. https:\/\/doi.org\/10.1007\/s00345-023-04509-6","journal-title":"World J Urol"},{"key":"11185_CR4","doi-asserted-by":"publisher","first-page":"102139","DOI":"10.1016\/j.canep.2022.102139","volume":"78","author":"A Adesina","year":"2022","unstructured":"Adesina A et al (2022) Prostate cancer in Sub-Saharan africa: epidemiology and management challenges. Cancer Epidemiol 78:102139. https:\/\/doi.org\/10.1016\/j.canep.2022.102139","journal-title":"Cancer Epidemiol"},{"issue":"6","key":"11185_CR5","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/nrc2029","volume":"2","author":"YJ Jung","year":"2001","unstructured":"Jung YJ, Pienta KJ (2001) Bone metastases in prostate cancer: emerging therapeutic strategies. Nat Rev Clin Oncol 2(6):356\u2013363. https:\/\/doi.org\/10.1038\/nrc2029","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"11185_CR6","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.urolonc.2021.07.003","volume":"40","author":"JM Fitzpatrick","year":"2022","unstructured":"Fitzpatrick JM, de Wit R, Wirth MP (2022) Castration-resistant prostate cancer: Mechanisms, targets, and treatment. Urol Oncol 40(1):12\u201321. https:\/\/doi.org\/10.1016\/j.urolonc.2021.07.003","journal-title":"Urol Oncol"},{"issue":"2","key":"11185_CR7","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41391-017-0038-1","volume":"21","author":"R Aggarwal","year":"2018","unstructured":"Aggarwal R et al (2018) Clinical and biological features of neuroendocrine prostate cancer. Prostate Cancer Prostatic Dis 21(2):147\u2013154. https:\/\/doi.org\/10.1038\/s41391-017-0038-1","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"11185_CR8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12943-022-01692-1","volume":"22","author":"Y Li","year":"2023","unstructured":"Li Y, Li S, Liu J (2023) Aberrant regulation of alternative splicing in cancer progression and therapy resistance. Mol Cancer 22(1):14. https:\/\/doi.org\/10.1186\/s12943-022-01692-1","journal-title":"Mol Cancer"},{"key":"11185_CR9","doi-asserted-by":"publisher","first-page":"671636","DOI":"10.3389\/fonc.2021.671636","volume":"11","author":"S Liu","year":"2021","unstructured":"Liu S, Cheng C, Zhang C (2021) Alternative splicing in prostate cancer and its clinical implications. Front Oncol 11:671636. https:\/\/doi.org\/10.3389\/fonc.2021.671636","journal-title":"Front Oncol"},{"issue":"6","key":"11185_CR10","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.molcel.2010.08.011","volume":"39","author":"V Tripathi","year":"2010","unstructured":"Tripathi V, Ellis JD, Shen Z, Song DY, Pan Q, Watt AT et al (2010) The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. Mol Cell 39(6):925\u2013938. https:\/\/doi.org\/10.1016\/j.molcel.2010.08.011","journal-title":"Mol Cell"},{"issue":"1","key":"11185_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0606-4","volume":"11","author":"N Amodio","year":"2018","unstructured":"Amodio N, Raimondi L, Juli G, Stamato MA, Caracciolo D, Tagliaferri P et al (2018) MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches. J Hematol Oncol 11(1):63. https:\/\/doi.org\/10.1186\/s13045-018-0606-4","journal-title":"J Hematol Oncol"},{"issue":"22","key":"11185_CR12","doi-asserted-by":"publisher","first-page":"19012","DOI":"10.18632\/oncotarget.4229","volume":"6","author":"F Wang","year":"2015","unstructured":"Wang F, Ren S, Chen R, Lu J, Shi X, Zhu Y et al (2015) Development and prospective multicenter evaluation of the long noncoding RNA MALAT-1 as a diagnostic urinary biomarker for prostate cancer. Oncotarget 6(22):19012\u201319021. https:\/\/doi.org\/10.18632\/oncotarget.4229","journal-title":"Oncotarget"},{"key":"11185_CR13","doi-asserted-by":"publisher","first-page":"1610488","DOI":"10.3389\/pore.2023.1610488","volume":"29","author":"M Taheri","year":"2023","unstructured":"Taheri M, Omrani MD, Ghafouri-Fard S (2023) Clinical significance of LncRNAs MALAT1 and TUG1 in human cancers. Pathol Oncol Res 29:1610488. https:\/\/doi.org\/10.3389\/pore.2023.1610488","journal-title":"Pathol Oncol Res"},{"issue":"2","key":"11185_CR14","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1530\/JME-14-0294","volume":"54","author":"Y Kong","year":"2015","unstructured":"Kong Y, Hsieh CH, Alonso LC (2015) TUG1 LncRNA functions in cancer and diabetes. J Mol Endocrinol 54(2):R1\u201312. https:\/\/doi.org\/10.1530\/JME-14-0294","journal-title":"J Mol Endocrinol"},{"issue":"11","key":"11185_CR15","doi-asserted-by":"publisher","first-page":"9206","DOI":"10.18632\/oncotarget.24238","volume":"9","author":"J Wang","year":"2018","unstructured":"Wang J, Liu X, Wu H, Ni P, Gu Z, Qiao Y et al (2018) Long non-coding RNA TUG1 promotes proliferation and metastasis in colorectal cancer via regulating miR-600\/CBX5 axis. Oncotarget 9(11):9206\u20139218. https:\/\/doi.org\/10.18632\/oncotarget.24238","journal-title":"Oncotarget"},{"issue":"5","key":"11185_CR16","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/s41419-020-2569-9","volume":"11","author":"TH Nguyen","year":"2020","unstructured":"Nguyen TH et al (2020) Long noncoding RNAs in stress response and apoptosis regulation. Cell Death Dis 11(5):385. https:\/\/doi.org\/10.1038\/s41419-020-2569-9","journal-title":"Cell Death Dis"},{"issue":"14","key":"11185_CR17","doi-asserted-by":"publisher","first-page":"6017","DOI":"10.1021\/acs.jmedchem.7b00401","volume":"60","author":"J Batson","year":"2017","unstructured":"Batson J, Toop HD, Redondo C, Babaei-Jadidi R, Chaikuad A, Wearmouth SF et al (2017) Development of potent, selective SRPK1 inhibitors as potential anticancer agents. J Med Chem 60(14):6017\u20136033. https:\/\/doi.org\/10.1021\/acs.jmedchem.7b00401","journal-title":"J Med Chem"},{"issue":"3","key":"11185_CR18","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.tips.2021.12.004","volume":"43","author":"J Duggan","year":"2022","unstructured":"Duggan J, Beusch I, Kielkopf CL (2022) Therapeutic modulation of pre-mRNA splicing by small-molecule inhibitors of serine\/arginine-rich protein kinases. Trends Pharmacol Sci 43(3):220\u2013234. https:\/\/doi.org\/10.1016\/j.tips.2021.12.004","journal-title":"Trends Pharmacol Sci"},{"key":"11185_CR19","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.semcancer.2023.102292","volume":"97","author":"F Wahid","year":"2025","unstructured":"Wahid F, Shehzad A, Khan T, Kim YY (2025) Role of SRPK1 in cancer biology: from splicing regulation to therapeutic targeting. Semin Cancer Biol 97:22\u201334. https:\/\/doi.org\/10.1016\/j.semcancer.2023.102292","journal-title":"Semin Cancer Biol"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-11185-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-025-11185-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-11185-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T10:35:20Z","timestamp":1762425320000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-025-11185-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["11185"],"URL":"https:\/\/doi.org\/10.1007\/s11033-025-11185-9","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]},"assertion":[{"value":"9 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"55"}}